$OTLK

$0.53 +$0.02 (3.21%) Close

$OTLK Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 243.4M shares outstanding

Who owns OTLK?

By type of holder

Institutions 7.9% Insiders 21.3% Everyone else 70.8%

Concentration Top 10 holders own 41.4%

Sukhtian Ghiath M. 17.5% · GMS Ventures & Investments 17.5%

Institutional ownership

7.9%

+3.5 pts vs last qtr

Institutional holders

+12 vs last qtr

Net shares bought

+8.5M

by institutions in Q2 2026

New / sold out

27 / 15

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Perceptive Advisors LLC NEW +3.1M
Vanguard Capital Management LLC +2.4M

Biggest sellers in Q2 2026

Armistice Capital, LLC SOLD OUT −4.2M
Commonwealth Equity Services, LLC SOLD OUT −470.0K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Outlook Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2023–FY2025

+178.2%

+66.79% a year

Each share's claim on the business

−64.1%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $19.8M

over 3 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years49% Under 1 year51%

Quarterly turnover

96.1%

of institutional shares changed hands

Top 10 managers, median time held

2.3 years

Super Investors

Investment managers reporting OTLK on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
VC Vanguard Capital Management LLC	4.4M	1.80%	+2.4M (+122.5%)	2024	0.0%
Shares held by quarter Peak holding4.4M (Q2'26) Change over 8 quarters+4.4M Share of the company1.800% Vanguard Capital Management LLC's full portfolio →
AC Armistice Capital, LLC	—	—	SOLD OUT	—	0.0%
Shares held by quarter Peak holding4.2M (Q1'26) Change over 8 quarters0 Armistice Capital, LLC's full portfolio →

Vanguard Capital Management LLC

4.4M

% of company

1.80%

Change vs last qtr

+2.4M (+122.5%)

Held since

2024

Armistice Capital, LLC

—

% of company

—

Change vs last qtr

SOLD OUT

Held since

—

28 more super investors behind a free account

See every manager holding Outlook Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting OTLK on Form N-PORT; together they hold 2.2% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$4.88M	3.1M	1.26%	0.00%	June 30, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$1.96M	1.2M	0.51%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$4.88M

% of company

1.26%

% of the fund

0.00%

As of

June 30, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$1.96M

% of company

0.51%

% of the fund

0.00%

As of

June 30, 2026

10 more funds behind a free account

See every fund holding Outlook Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
SG Sukhtian Ghiath M. 5%+ holder 13D · 16.4%	42.6M	17.51%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company17.510% Disclosed stake13D · 16.4% View the 13D/G filing →
GV GMS Ventures & Investments 5%+ holder 13D · 16.4%	42.6M	17.51%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company17.510% Disclosed stake13D · 16.4% View the 13D/G filing →

Sukhtian Ghiath M.

5%+ holder13D · 16.4%

42.6M

% of company

17.51%

Change vs last qtr

—

Held since

—

GMS Ventures & Investments

5%+ holder13D · 16.4%

42.6M

% of company

17.51%

Change vs last qtr

—

Held since

—

6 more holders behind a free account

See every insider and 5%+ holder of Outlook Therapeutics Inc.

Comments